Talphera Inc (FRA:R5XA)
€ 0.46 -0.138 (-23.08%) Market Cap: 8.66 Mil Enterprise Value: -1.23 Mil PE Ratio: 0 PB Ratio: 0.89 GF Score: 39/100

Q4 2022 AcelRx Pharmaceuticals Inc Earnings Call Transcript

Mar 30, 2023 / 08:30PM GMT
Release Date Price: €0.6615 (-0.38%)
Operator

Welcome to the AcelRx 2022 Full Year and Fourth Quarter Financial Results Conference Call. This call is being webcast live via the Events page on the Investors section of AcelRx's website at www.acelrx.com. This call is the property of AcelRx, and any recording, reproduction or transmission of this call without the expressed written consent of AcelRx is strictly prohibited.

As a reminder, today's webcast presentation is being recorded. You may listen to a replay of this webcast by going to the Investors section of AcelRx's website. (Operator Instructions)

I would now like to turn the call over to Raffi Asadorian, AcelRx Chief Financial Officer.

Raffi Mark Asadorian
AcelRx Pharmaceuticals, Inc. - CFO

Thank you, Andrew. Thank you for joining us on the call today. This afternoon, we announced our full year and fourth quarter 2022 financial results and associated business updates in a press release. This press release can be found with the investors within the Investors section of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot